Ocera Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 78   

Articles published

OCRX 3.80 +0.29 (8.26%)
price chart
Ocera Therapeutics, Inc. (OCRX) Files Form 4 Insider Buying : Wendall ...
Ocera Therapeutics, Inc. (OCRX): Wendall Wierenga , director of Ocera Therapeutics, Inc. purchased 5,000 shares on Jun 23, 2015.
Moving Stocks: Microsoft Corporation (NASDAQ:MSFT), Twitter Inc (NYSE:TWTR ...  Stock Transcript
Ocera Therapeutics Finally Ready To Reward Investors
Furthermore, to bluntly state the obvious, Ocera has had a rough 2014. Investors unfamiliar with the company would probably look at the stock chart and move on to the next assuming that something catastrophic had occurred to warrant such a steep price ...
Ocera Therapeutics, Inc. (OCRX) Discloses Form 4 Insider Buying : Exec ...
Ocera Therapeutics, Inc. (OCRX) Discloses Insider Transaction. Wendall Wierenga , director of Ocera Therapeutics, Inc. purchased 5,000 shares on Jun 23, 2015. The Insider buying transaction was disclosed on Jun 24, 2015 to the Securities and Exchange ...
Linda Grais the President and CEO of Ocera Therapeutics Inc (NASDAQ:OCRX ...
Linda Grais, President and CEO of Ocera Therapeutics Inc (NASDAQ:OCRX) 3.75 +0.01 0.27% is the insider, Octafinance want to inform you about.
Gaurav Aggarwal Acquires 7500 Shares of Ocera Therapeutics Stock (OCRX)  sleekmoney
Ocera Therapeutics CEO Linda S. Grais Buys 30000 Shares (OCRX)  The Legacy
Ocera Therapeutics to Report Pipeline Progress and First Quarter 2015 ...
PALO ALTO, Calif., April 22, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it will release its first quarter 2015 ...
Ocera Therapeutics to Present at the JMP Securities Life Sciences Conference
PALO ALTO, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Gaurav Aggarwal, M.D.
Zacks Downgrades Ocera Therapeutics to Sell (OCRX)
Ocera Therapeutics (NASDAQ:OCRX) was downgraded by Zacks from a “hold” rating to a “sell” rating in a note issued to investors on Monday.
Ocera Therapeutics Stock Rating Lowered by Zacks (OCRX)  sleekmoney
Today's Morning Thoughts: Ocera Therapeutics, Inc. (OCRX), Tallgrass ...  WallStreet Scope
Ocera Therapeutics to Present at the Jefferies 2015 Healthcare Conference
PALO ALTO, Calif., May 29, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D.
Ocera Therapeutics to Announce Fourth Quarter and Full Year 2014 Financial ...
PALO ALTO, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it will release its fourth quarter and ...
Ocera Therapeutics' (OCRX) CEO Linda Grais on Q3 2014 Results - Earnings ...
Welcome to Ocera Therapeutics Q3 Earnings Call. This call is being webcast live on the Events page of the Investor section of Ocera's Web site at www.ocera.com. Pardon me its www.ocerainc.com. This call is the property of Ocera and any recording, ...
Related articles »